JP2016520595A5 - - Google Patents

Download PDF

Info

Publication number
JP2016520595A5
JP2016520595A5 JP2016515273A JP2016515273A JP2016520595A5 JP 2016520595 A5 JP2016520595 A5 JP 2016520595A5 JP 2016515273 A JP2016515273 A JP 2016515273A JP 2016515273 A JP2016515273 A JP 2016515273A JP 2016520595 A5 JP2016520595 A5 JP 2016520595A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
chain variable
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016515273A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016520595A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/KR2014/004579 external-priority patent/WO2014189306A1/ko
Publication of JP2016520595A publication Critical patent/JP2016520595A/ja
Publication of JP2016520595A5 publication Critical patent/JP2016520595A5/ja
Pending legal-status Critical Current

Links

JP2016515273A 2013-05-22 2014-05-22 抗TNF−α/CXCL10二重ターゲット抗体及びその用途 Pending JP2016520595A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR10-2013-0057762 2013-05-22
KR20130057762 2013-05-22
KR10-2013-0057475 2013-05-22
KR20130057475 2013-05-22
PCT/KR2014/004579 WO2014189306A1 (ko) 2013-05-22 2014-05-22 항 TNF-α/CXCL10 이중 타겟 항체 및 그의 용도

Publications (2)

Publication Number Publication Date
JP2016520595A JP2016520595A (ja) 2016-07-14
JP2016520595A5 true JP2016520595A5 (enExample) 2017-06-01

Family

ID=51933801

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016515273A Pending JP2016520595A (ja) 2013-05-22 2014-05-22 抗TNF−α/CXCL10二重ターゲット抗体及びその用途

Country Status (11)

Country Link
US (1) US10087248B2 (enExample)
EP (1) EP3000827B1 (enExample)
JP (1) JP2016520595A (enExample)
KR (1) KR101671955B1 (enExample)
CN (1) CN105263964A (enExample)
AU (1) AU2014269287B2 (enExample)
BR (1) BR112015029224A2 (enExample)
CA (1) CA2913118A1 (enExample)
HK (1) HK1223112A1 (enExample)
PH (1) PH12015502601A1 (enExample)
WO (1) WO2014189306A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ789594A (en) 2016-06-20 2025-07-25 Kymab Ltd Anti-PD-L1 antibodies
US20210246227A1 (en) * 2017-05-31 2021-08-12 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
WO2019197979A1 (en) * 2018-04-10 2019-10-17 Y-Biologics Inc. Cell engaging binding molecules
US10633458B2 (en) 2018-04-10 2020-04-28 Y-Biologics Inc. Cell engaging binding molecules
KR102088789B1 (ko) * 2018-06-20 2020-03-13 인하대학교 산학협력단 항 TNF/IFN scFv-Fc 이중 표적 항체 및 이의 이용
KR102323342B1 (ko) 2019-04-26 2021-11-08 주식회사 와이바이오로직스 IL-17A 및 TNF-α에 특이적으로 결합하는 이중표적 항체
KR102385046B1 (ko) 2020-08-24 2022-04-13 에스큐엔지니어링(주) 드론에 탈부착 점검장치를 이용한 다목적 구조물 검사장치
BR112023020167A2 (pt) * 2021-03-31 2023-12-12 Univ California Fusões agente-ligante de ligação biespecífica para a degradação de proteínas alvo
KR102357756B1 (ko) 2021-05-14 2022-02-09 유한회사 서해항공방제 드론을 이용한 유해 조수 및 곤충 방제장치 및 그를 구비하는 드론
CN114432502B (zh) * 2021-12-31 2023-02-03 中山大学附属第八医院(深圳福田) 一种负载op3-4多肽、抗cxcl9抗体的水凝胶及其制备方法与应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103275221B (zh) * 1996-02-09 2016-08-17 艾伯维生物技术有限公司 结合人TNFα的人抗体
WO2005023201A2 (en) 2003-09-09 2005-03-17 Medarex, Inc. Methods for treating rheumatoid arthritis
JP2008534508A (ja) 2005-03-22 2008-08-28 メドスター ヘルス インコーポレイテッド 心血管疾患を診断および処置するための送達システムおよび方法
CA2608728A1 (en) * 2005-05-16 2006-11-23 Abbott Biotechnology Ltd. Use of tnfa inhibitor for treatment of erosive polyarthritis
AU2006261357A1 (en) * 2005-06-17 2006-12-28 Zimmer Spine Austin, Inc. Improved method of treating degenerative spinal disorders
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CA2618482C (en) * 2005-08-19 2014-10-07 Abbott Laboratories Dual variable domain immunoglobin and uses thereof
JP2012228248A (ja) * 2005-08-19 2012-11-22 Abbott Lab 二重可変ドメイン免疫グロブリン及びその使用
AR069495A1 (es) 2007-11-30 2010-01-27 Glaxo Group Ltd Construcciones de union de antigenos para el tratamiento de cancer o enfermedades inflamatorias (asma, artritis o artrosis)
WO2011090762A1 (en) 2009-12-29 2011-07-28 Emergent Product Development Seattle, Llc Heterodimer binding proteins and uses thereof
ES2682081T3 (es) * 2011-10-11 2018-09-18 F. Hoffmann-La Roche Ag Ensamblaje mejorado de anticuerpos biespecíficos
KR20130121601A (ko) 2012-04-27 2013-11-06 주식회사에이앤알쎄라퓨틱스 인간 항 cxcl-10 항체 및 이를 포함하는 류마티스 관절염 치료용 조성물

Similar Documents

Publication Publication Date Title
JP2016520595A5 (enExample)
JP2022177090A5 (enExample)
JP2013542194A5 (enExample)
JP2014500009A5 (enExample)
JP2018521691A5 (enExample)
HRP20220811T1 (hr) Agonistička sredstva za vezanje tnf receptora
JP2018536393A5 (enExample)
RU2018106364A (ru) Антитела против рецептора tfr и их применение при лечении пролиферативных и воспалительных расстройств
JP2012116856A5 (enExample)
JP2018521638A5 (enExample)
JP2013543384A5 (enExample)
JP2015533795A5 (enExample)
JP2015514110A5 (enExample)
JP2015503909A5 (enExample)
JP2016538876A5 (enExample)
JP2020522280A5 (enExample)
JP2011502137A5 (enExample)
JP2011527899A5 (enExample)
JP2021500916A5 (enExample)
JP2020511946A5 (enExample)
SI2768859T1 (en) Antagonists of il17c for the treatment of inflammatory disorders
AR104906A1 (es) Anticuerpos dirigidos a la proteína morfogenética ósea 9 (bmp9) y métodos a partir de estos
JP2020522281A5 (enExample)
RU2014127287A (ru) Антитела, используемые для пассивной вакцинации против гриппа
RU2019111862A (ru) Новые антитела против фактора xi и их применения